



Molecular Networks
Inspiring Chemical Discovery

Optibrium and Molecular Networks Collaborate to Share Complementary Technology Platforms

CAMBRIDGE, United Kingdom and ERLANGEN, Germany, September 15, 2009 – Optibrium Ltd. and Molecular Networks GmbH today announce plans to further intensify their collaboration and share complementary technology platforms. The companies demonstrated their cooperation with the integration of Molecular Networks' premium 3D structure generator CORINA into StarDrop, Optibrium's intuitive platform for guiding compound selection and design decisions in drug discovery.

CORINA is used within StarDrop's predictive P450 metabolism models which identify metabolic liabilities of candidate molecules against the major cytochrome P450 enzymes. Based on CORINA-generated 3D structures, the predictions of StarDrop's P450 metabolism models assist scientists to selectively redesign molecules in order to overcome possible metabolism problems or drug-drug interactions.

Dr. Matthew Segall, CEO of Optibrium, commented "The seamless integration of CORINA within StarDrop has enabled our P450 metabolism models to provide more reliable data in support of the drug design and optimisation process. We are looking forward to providing access to more of Molecular Network's chemoinformatics tools through StarDrop to further benefit our customers." Prof. Johann Gasteiger, CEO of Molecular Networks said that "We are happy that our technology can again successfully contribute to the drug discovery value chain." He adds, "As Dr. Segall already pointed out, the winners are the users of StarDrop to design better drugs much faster and we are excited about future collaboration with Dr. Segall and Optibrium."

About Optibrium. Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Optibrium's primary product, StarDrop, is focused on the drug discovery industry, helping scientists to guide decisions in the design and selection of potential drug molecules. Optibrium was founded in 2009 as a spin-out of BioFocus DPI (formerly Inpharmatica). The founding group was responsible for the development of StarDrop from 2003 and, prior to this, research and development of related technologies since 1994. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups.

About Molecular Networks. Molecular Networks (www.molecular-networks.com) offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997 and headquartered in Erlangen, Germany, Molecular Networks' technology is utilized worldwide in major industrial and academic discovery laboratories to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support systems for the design and the synthesis of chemical compounds and for the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.

Contacts

Dr Matthew Segall
Optibrium Ltd.
+44-1223-815900
press@optibrium.com

Dr. Christof H. Schwab
Molecular Networks GmbH
+49-9131-815670
schwab@molecular-networks.com